FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028996978> ?p ?o ?g. }

• W2028996978 endingPage "253" @default.
• W2028996978 startingPage "244" @default.
• W2028996978 abstract "Objective The present study examined the effects of intraportal infusion of L-arginine on ischemia/reperfusion injury (I/RI) in pig livers, by observing changes in the liver function, liver cell morphology, and changes in the mitochondrial ultrastructure. Background The involvement of the nitric oxide (NO) pathway in the reperfusion-ischemic phenomenon is complex and not fully understood. Likewise, little is known about the possible benefit of intraportal infusion of L-arginine (substrate for the NO synthesis) on liver I/RI. Methods A pig model consisting of 90 min of hepatic ischemia and 180 min of reperfusion was employed. Eighteen female hybrid pigs were randomly divided into three groups: sham-operated, non-preconditioned, and pharmacologically preconditioned group (intraportal infusion of L-arginine 400 mg/kg) 10 min before being subjected to ischemia and reperfusion. Serum concentrations of aspartate aminotransferase (AST), alanine aminotransferase (ALT), thiobarbituric acid reactive substances (TBARS), and the bile flow were measured. Liver biopsies were taken 180 min after reperfusion for histology, caspase-3 immunohistochemistry, and ultrastructural examination of mitochondria. Results In the pharmacologically preconditioned group, we observed increased bile flow (P < 0.01) and improved serum AST levels (P < 0.01) relative to the non-preconditioned group. Serum concentrations of TBARS did not differ between the groups. Sinusoidal congestion (P = 0.02) was more evident in the non-preconditioned group than in the sham operated group. Infiltrating PMNs (P = 0.01) were more evident in the non-preconditioned group than in the sham and pharmacologically preconditioned group. The pharmacologically preconditioned group showed an approximately 2.5-fold decrease in caspase-3 activity relative to the non-preconditioned group (P < 0.01). Notably, damage to the mitochondrial ultrastructure in the pharmacologically preconditioned group was reduced relative to the other groups (P < 0.01). Conclusions Pharmacological preconditioning with intraportal L-arginine provided protection against hepatic I/RI in early phases of the reperfusion period. The mechanisms underlying the protective effect may include preservation of the mitochondrial structure and inhibition of caspase-3 activity. The present study examined the effects of intraportal infusion of L-arginine on ischemia/reperfusion injury (I/RI) in pig livers, by observing changes in the liver function, liver cell morphology, and changes in the mitochondrial ultrastructure. The involvement of the nitric oxide (NO) pathway in the reperfusion-ischemic phenomenon is complex and not fully understood. Likewise, little is known about the possible benefit of intraportal infusion of L-arginine (substrate for the NO synthesis) on liver I/RI. A pig model consisting of 90 min of hepatic ischemia and 180 min of reperfusion was employed. Eighteen female hybrid pigs were randomly divided into three groups: sham-operated, non-preconditioned, and pharmacologically preconditioned group (intraportal infusion of L-arginine 400 mg/kg) 10 min before being subjected to ischemia and reperfusion. Serum concentrations of aspartate aminotransferase (AST), alanine aminotransferase (ALT), thiobarbituric acid reactive substances (TBARS), and the bile flow were measured. Liver biopsies were taken 180 min after reperfusion for histology, caspase-3 immunohistochemistry, and ultrastructural examination of mitochondria. In the pharmacologically preconditioned group, we observed increased bile flow (P < 0.01) and improved serum AST levels (P < 0.01) relative to the non-preconditioned group. Serum concentrations of TBARS did not differ between the groups. Sinusoidal congestion (P = 0.02) was more evident in the non-preconditioned group than in the sham operated group. Infiltrating PMNs (P = 0.01) were more evident in the non-preconditioned group than in the sham and pharmacologically preconditioned group. The pharmacologically preconditioned group showed an approximately 2.5-fold decrease in caspase-3 activity relative to the non-preconditioned group (P < 0.01). Notably, damage to the mitochondrial ultrastructure in the pharmacologically preconditioned group was reduced relative to the other groups (P < 0.01). Pharmacological preconditioning with intraportal L-arginine provided protection against hepatic I/RI in early phases of the reperfusion period. The mechanisms underlying the protective effect may include preservation of the mitochondrial structure and inhibition of caspase-3 activity." @default.
• W2028996978 created "2016-06-24" @default.
• W2028996978 creator A5014590093 @default.
• W2028996978 creator A5041664765 @default.
• W2028996978 creator A5062434896 @default.
• W2028996978 creator A5070396685 @default.
• W2028996978 creator A5084146838 @default.
• W2028996978 date "2009-08-01" @default.
• W2028996978 modified "2023-09-26" @default.
• W2028996978 title "Pharmacological Preconditioning Using Intraportal Infusion of L-Arginine Protects Against Hepatic Ischemia Reperfusion Injury" @default.
• W2028996978 cites W1537971445 @default.
• W2028996978 cites W1821918060 @default.
• W2028996978 cites W1825808183 @default.
• W2028996978 cites W1878685619 @default.
• W2028996978 cites W1968505668 @default.
• W2028996978 cites W1972089133 @default.
• W2028996978 cites W1981704818 @default.
• W2028996978 cites W1986596262 @default.
• W2028996978 cites W1989611868 @default.
• W2028996978 cites W1989729441 @default.
• W2028996978 cites W1993420174 @default.
• W2028996978 cites W1998178297 @default.
• W2028996978 cites W1998415599 @default.
• W2028996978 cites W1998489692 @default.
• W2028996978 cites W1999748694 @default.
• W2028996978 cites W2003874040 @default.
• W2028996978 cites W2008201824 @default.
• W2028996978 cites W2009000520 @default.
• W2028996978 cites W2009601307 @default.
• W2028996978 cites W2011573544 @default.
• W2028996978 cites W2013517113 @default.
• W2028996978 cites W2020321505 @default.
• W2028996978 cites W2024647424 @default.
• W2028996978 cites W2029999927 @default.
• W2028996978 cites W2036155002 @default.
• W2028996978 cites W2044124970 @default.
• W2028996978 cites W2045123815 @default.
• W2028996978 cites W2049839784 @default.
• W2028996978 cites W2051104901 @default.
• W2028996978 cites W2052450090 @default.
• W2028996978 cites W2069536567 @default.
• W2028996978 cites W2069810984 @default.
• W2028996978 cites W2070357652 @default.
• W2028996978 cites W2071739435 @default.
• W2028996978 cites W2094922589 @default.
• W2028996978 cites W2100160047 @default.
• W2028996978 cites W2105862508 @default.
• W2028996978 cites W2109025390 @default.
• W2028996978 cites W2113226850 @default.
• W2028996978 cites W2117825601 @default.
• W2028996978 cites W2119224030 @default.
• W2028996978 cites W2127911529 @default.
• W2028996978 cites W2130866079 @default.
• W2028996978 cites W2132421073 @default.
• W2028996978 cites W2136314375 @default.
• W2028996978 cites W2137671873 @default.
• W2028996978 cites W2143796432 @default.
• W2028996978 cites W2154346380 @default.
• W2028996978 cites W2161949681 @default.
• W2028996978 cites W2165566422 @default.
• W2028996978 cites W2184023957 @default.
• W2028996978 cites W2209831038 @default.
• W2028996978 cites W2360157829 @default.
• W2028996978 doi "https://doi.org/10.1016/j.jss.2008.07.002" @default.
• W2028996978 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19540520" @default.
• W2028996978 hasPublicationYear "2009" @default.
• W2028996978 type Work @default.
• W2028996978 sameAs 2028996978 @default.
• W2028996978 citedByCount "13" @default.
• W2028996978 countsByYear W20289969782012 @default.
• W2028996978 countsByYear W20289969782013 @default.
• W2028996978 countsByYear W20289969782014 @default.
• W2028996978 countsByYear W20289969782015 @default.
• W2028996978 crossrefType "journal-article" @default.
• W2028996978 hasAuthorship W2028996978A5014590093 @default.
• W2028996978 hasAuthorship W2028996978A5041664765 @default.
• W2028996978 hasAuthorship W2028996978A5062434896 @default.
• W2028996978 hasAuthorship W2028996978A5070396685 @default.
• W2028996978 hasAuthorship W2028996978A5084146838 @default.
• W2028996978 hasConcept C126322002 @default.
• W2028996978 hasConcept C134018914 @default.
• W2028996978 hasConcept C185592680 @default.
• W2028996978 hasConcept C2776151105 @default.
• W2028996978 hasConcept C2777352226 @default.
• W2028996978 hasConcept C2777468819 @default.
• W2028996978 hasConcept C2777504301 @default.
• W2028996978 hasConcept C2779311647 @default.
• W2028996978 hasConcept C2780114680 @default.
• W2028996978 hasConcept C2780829032 @default.
• W2028996978 hasConcept C42219234 @default.
• W2028996978 hasConcept C515207424 @default.
• W2028996978 hasConcept C519581460 @default.
• W2028996978 hasConcept C541997718 @default.
• W2028996978 hasConcept C55493867 @default.
• W2028996978 hasConcept C71924100 @default.
• W2028996978 hasConcept C98274493 @default.
• W2028996978 hasConceptScore W2028996978C126322002 @default.
• W2028996978 hasConceptScore W2028996978C134018914 @default.

• next